Centre Hospitalier Universitaire De Caen Normandie

At Centre Hospitalier Universitaire De Caen Normandie, the clinical research portfolio strongly features hematologic malignancies and related blood disorders. Studies focus on diseases such as acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, and lymphoma, with the goal of improving treatment effectiveness, deepening remission, and refining transplant-related care.

• Trials in acute myeloid leukemia and myelodysplastic syndrome are evaluating new approaches to induction and transplant strategies.
• Research in multiple myeloma is examining maintenance and long-term disease control after stem cell transplantation.
• Studies in lymphoma are testing novel combinations to improve response and progression-free survival.

This area also includes work on allogeneic stem cell transplantation and supportive care, aiming to improve survival while reducing complications for patients with difficult-to-treat blood cancers.

The site is active in neoplasm research across several solid tumors, including non-small cell lung cancer, hepatocellular carcinoma, biliary tract carcinoma, colorectal cancer, and small bowel adenocarcinoma. These trials are designed to test new therapies, improve survival, and expand treatment options for advanced or high-risk disease.

• Non-small cell lung cancer studies are comparing modern combinations for metastatic and locally advanced disease.
• Hepatocellular carcinoma research is exploring new immunotherapy-based strategies for unresectable and advanced disease.
• Trials in biliary tract carcinoma and small bowel adenocarcinoma are assessing whether new regimens can improve outcomes after diagnosis or surgery.

Overall, this oncology program reflects a strong interest in better disease control for patients with cancers that remain challenging to treat.

Research in immune system diseases at the Centre Hospitalier Universitaire De Caen Normandie includes giant cell arteritis, systemic lupus erythematosus, Sjögren’s syndrome, and ulcerative colitis. These studies aim to improve symptom control, maintain remission, and evaluate whether newer therapies can offer better long-term disease management.

• Giant cell arteritis trials are focused on treatment discontinuation and relapse prevention.
• Studies in systemic lupus erythematosus and Sjögren’s syndrome are evaluating safety and effectiveness of immune-targeted treatments.
• Ulcerative colitis research is assessing therapies intended to support clinical remission.

This field emphasizes better control of chronic inflammatory disease while reducing the burden of ongoing treatment.

The cardiovascular portfolio includes acute myocardial infarction, atrial fibrillation, atherosclerotic cardiovascular disease, and valve-related care. These trials are designed to prevent major cardiovascular events, reduce bleeding risk, and improve outcomes after heart-related procedures.

• Studies in atrial fibrillation are comparing approaches to prevent stroke and systemic embolism.
• Research in acute myocardial infarction is evaluating strategies for faster and safer treatment in people at risk of recurrence.
• Work in transcatheter aortic valve implantation is focused on improving peri-procedural safety and recovery.

These trials reflect a broader effort to improve prevention and treatment in high-risk cardiovascular patients.

A notable research theme at this hospital is kidney transplant and allogeneic hematopoietic cell transplantation. The studies examine how to prevent rejection, reduce graft-versus-host disease, and improve transplant success in patients with complex medical needs.

• In kidney transplant, investigators are comparing approaches to lower rejection risk.
• In blood cancer transplantation, trials are testing better ways to prevent graft-versus-host disease.
• Several studies aim to improve safety after transplant while maintaining effective disease control.

This area combines clinical hematology expertise with long-term transplant care to support better recovery and survival.

The site also contributes to respiratory tract diseases and virus diseases research, including respiratory syncytial virus, interstitial lung disease, and HIV-1. These trials are intended to improve prevention, assess safety, and support better disease control in vulnerable patient groups.

• Respiratory syncytial virus studies are evaluating prevention strategies for infants and children at higher risk.
• Research in interstitial lung disease is focused on improving lung function and slowing progression.
• HIV-1 work is examining whether treatment options remain effective in patients with prior resistance-related mutations.

These studies show a practical emphasis on prevention, long-term safety, and better management of chronic or high-risk infectious and pulmonary conditions.

Nervous system diseases and selected rare conditions are also represented, including multiple sclerosis and lymphatic malformations. The research is aimed at comparing treatment options, reducing disease activity, and improving quality of life for patients with long-term conditions.

• Multiple sclerosis studies are comparing therapies to maintain control of disease activity over time.
• Research in lymphatic malformations is exploring targeted treatment for mutation-associated disease.
• These trials highlight interest in both chronic neurologic disease and uncommon pediatric or congenital conditions.

The program reflects a broad commitment to improving care where standard treatment options may be limited.